公开(公告)号：US20180267022A1

公开(公告)日：2018-09-20

申请号：US15542263

申请日：2016-02-26

Applicant: AMOREPACIFIC CORPORATION

Inventor： Chang Seok LEE ,  Heung Soo BAEK ,  Yung Hyup JOO ,  Jeong Hwan KIM ,  Hong-Ju SHIN ,  Mi Young PARK ,  Song Seok SHIN

IPC: G01N33/50

CPC classification number: G01N33/5044 ,  G01N33/5014

Abstract: In one aspect of the present specification, provided is a method for predicting a side effect of a whitening ingredient, the method comprising measuring at least one of i) the increase in toxicity according to long-term use of a whitening ingredient, ii) the difference between a concentration having whitening effect and a concentration having cell toxicity, and iii) the increase in sensitivity to the whitening ingredient according to ultraviolet pretreatment. In addition, the method has an effect of effectively predicting whether a side effect will occur if the whitening ingredient is used for a long time.

公开(公告)号：US20200215040A1

公开(公告)日：2020-07-09

申请号：US16638038

申请日：2018-08-10

Applicant: AMOREPACIFIC CORPORATION

Inventor： Joon Ho CHOI ,  Won Kyung CHO ,  Kwang-Hyun SHIN ,  Byoung Young WOO ,  Ki-Wha LEE ,  Min-Soo KIM ,  Jong Hwa ROH ,  Mi Young PARK ,  Young-Ho PARK ,  Eun Sil PARK ,  Jae Hong PARK

IPC: A61K31/44 ,  A61K47/38 ,  A61K9/00

Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.